Search results
Results From The WOW.Com Content Network
June 25, 2024 at 3:54 AM. (Reuters) -AstraZeneca's blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type ...
Imfinzi clocked $4.24 billion in sales in 2023, and is a blockbuster medicine in AstraZeneca's key oncology portfolio, which makes up more than 20% of its total revenues.
Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).
May 17, 2024 at 5:40 PM. By Blake Brittain. (Reuters) - AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung ...
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2] [3] [4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
Rank Drug Main indication Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban
After Boston Scientific increased their offer to $25 billion, Johnson & Johnson further increased their offer to $24.2 billion. 105 2017 PPG Industries: Akzo Nobel: 24.1 30 Akzo rejected the unsolicited offer, claiming the revised offer was still too low. 106 1998 Bank of New York: Mellon Bank Corporation: 24.0 44.9
The JCVI is meeting on Thursday, with a decision on who should get a third booster shot expected in the coming days. Pfizer and AstraZeneca vaccines ‘are safe to use as booster shots’ Skip to ...